Rising Cancer Prevalence Fueling The Growth Due To Increasing Demand For Targeted Immunotherapies Emerges as a Core Driver of the Natural Killer (NK) Cell Therapeutics Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Natural Killer (NK) Cell Therapeutics Market Through 2025?
The market size for natural killer (NK) cell therapeutics has expanded swiftly in the last few years. Projected to increase from $3.52 billion in 2024 to $3.93 billion in 2025, with a compound annual growth rate (CAGR) of 11.6%. This substantial growth in the previous period is attributable to the surge in cancer cases, enhanced R&D funding, increased understanding of immunotherapy, growth in strategic partnerships within the industry, amplified regulatory backing, and advancements in cell expansion technologies.

What's the Projected Size of the Global Natural Killer (NK) Cell Therapeutics Market by 2029?
The market size for natural killer (NK) cell therapeutics is predicted to witness substantial expansion in the approaching years, swelling to $6.17 billion in 2029 with a compound annual growth rate (CAGR) of 12.0%. This projected growth during the forecast period can be ascribed to factors such as the increase in clinical trials, escalated investment in immunotherapy research and development, wider usage in solid tumors, strategic partnerships, regulatory backing for cell therapies, and the escalating demand from patients for customized cancer treatments. Key trends anticipated during the forecast period encompass breakthroughs in genetic engineering, advancements in CAR-NK therapies, evolution of cell expansion methods, novel developments in clinical trial activities, production of ready-to-use NK cell products, and progress in solid tumor treatment methods.

View the full report here:
https://www.thebusinessresearchcompany.com/report/natural-killer-nk-cell-therapeutics-global-market-report

Top Growth Drivers in the Natural Killer (NK) Cell Therapeutics Industry: What's Accelerating the Market?
The escalating rates of cancer are likely to stimulate the expansion of the natural killer (NK) cell therapeutics market. Cancer is characterized by the uncontrolled proliferation of atypical cells, which invade surrounding tissues and metastasize to other parts of the body. This deregulation of normal cell activity results in tumor formation and bodily impairment. Factors such as environmental exposure to pollutants, tobacco smoke, and chemicals can harm the deoxyribonucleic acid (DNA) and interfere with cell function, thereby heightening the risk of cancer. NK cell therapeutics aid in cancer treatment by targeting and eliminating tumor cells without any prior sensitization. For instance, the American Cancer Society, a US-based non-profit organization, reported in April 2024 that 20 million new cancer cases were identified and 9.7 million individuals succumbed to the disease worldwide in 2022. By 2050, solely due to anticipated population growth, the count of cancer cases is expected to escalate to 35 million. Consequently, the increasing incidence of cancer is promoting the growth of the natural killer (NK) cell therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24328&type=smp

Which Emerging Trends Are Transforming the Natural Killer (NK) Cell Therapeutics Market in 2025?
Prominent businesses in the natural killer (NK) cell therapeutics market are concentrating on innovations such as devising scalable iPSC-based NK cell manufacturing infrastructures, which will facilitate cost-efficient, readily available NK cell treatments. These infrastructures employ induced pluripotent stem cells (iPSCs) to produce NK cells in a standardized, feeder-free, confined bioreactor setting, guaranteeing high yields and regulatory complaisance. For example, in April 2025, the Belgium-based biotechnology research firm, Cellistic, introduced the Echo-NK platform, an iPSC-centric manufacturing solution for NK cell therapies. The platform provides scalable production of NK cells aimed at targeting blood cancers, solid tumors, and autoimmune diseases, executing all critical expansion processes in confined bioreactor environments within Cellistic's EMA-certified GMP establishment. By incorporating Cellistic's Pulse cell line development skills and proprietary STAR-CRISPR technology, the Echo-NK platform expedites the timelines for producing stable iPSC cell lines with particular gene edits, delivering a commercially sustainable solution for readily available NK cell therapies.

What Are the Main Segments in the Natural Killer (NK) Cell Therapeutics Market?
The natural killer (nk) cell therapeutics market covered in this report is segmented -

1) By Therapeutics: Natural Killer (NK) Cell Directed Antibodies, Natural Killer (NK) Cell Therapies
2) By Application: Immunoproliferative Disorders, Gastrointestinal Diseases, Cancer, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Direct Tender, Other Distribution Channels
4) By End User: Research And Academic Institutes, Hospitals, Specialty Clinics

Subsegments:
1) By Natural Killer (NK) Cell Directed Antibodies: Monoclonal Antibodies (mAbs), Bispecific Antibodies (BsAbs), Antibody-Drug Conjugates (ADCs)
2) By Natural Killer (NK) Cell Therapies: Autologous NK Cell Therapies, Allogeneic NK Cell Therapies, Chimeric Antigen Receptor (CAR)-NK Cell Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24328&type=smp

Which Top Companies are Driving Growth in the Natural Killer (NK) Cell Therapeutics Market?
Major companies operating in the natural killer (NK) cell therapeutics market are Sanofi S.A., Thermo Fisher Scientific, Lonza AG, Catalent, Kite Pharma, Fate Therapeutics, Artiva Biotherapeutics, Nkarta, Inc, Celularity Inc., NKGen Biotech, Dragonfly Therapeutics, Cytovia Therapeutics, Glycostem Therapeutics, Gamida Cell, ONK Therapeutics, Wugen Inc., AGC Biologics, CytoImmune Therapeutics, XNK Therapeutics, Indapta Therapeutics, Neukio Biotherapeutics, Senti Biosciences, WuXi Advanced Therapies, Kiadis Pharma

Which Regions Will Dominate the Natural Killer (NK) Cell Therapeutics Market Through 2029?
North America was the largest region in the natural killer (NK) cell therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the natural killer (NK) cell therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24328

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.